Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT)Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion vaccine): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1401
BMT CTN 1401 is an academically led randomized study of a personalized cancer vaccine in which the combination of DC/MM fusion vaccine and lenalidomide maintenance after autoHCT is compared with maintenance alone as upfront treatment of MM (NCT#02728102). Assessment of the percentage of patients achieving CR and therapy-induced changes in MM-specific immunity are the primary clinical and immunologic endpoints, respectively. The protocol represents a transformative open source approach to cell therapy in MM and required collection of tumor cells prior to treatment initiation and vaccine production at day 60 after autoHCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: David E. Avigan, Nina Shah, Brent Logan, Jiaxi Zhu, Lina Bisharat, Natalie S. Callander, Thinle Chodon, Binod Dhakal, Yvonne A. Efebera, Nancy Geller, Peiman Hematti, Michele Herman, Hillard M. Lazarus, David H. McKenna, Courtney Nelson, Ajay Nooka, Kelly Tags: 83 Source Type: research
More News: Allergy & Immunology | Biology | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Hematology | Myeloma | Revlimid | Study | Transplants | Vaccines